Abstract Body

Background: Access to antiretroviral therapy (ART) has increased significantly in the last decade: 9.7 million people were on ART at the end of 2012, 2.9% only on second line. WHO recommends the use of a ritonavir boosted Protease Inhibitor (PI/b) containing regimen in patients failing a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-based first line, but evidence for the choice of combination is lacking. Methodology: A 48 weeks, randomized, open label, non-inferiority trial in 3 African cities (Yaounde – Cameroon, Bobo Dioulasso – Burkina Faso, Dakar – Senegal) comparing efficacy and safety of 3 second line regimens: Arm A: tenofovir (TDF)/emtricitabine (FTC) + lopinavir/ritonavir (LPV/r), reference arm, Arm B: abacavir (ABC) + didanosine (ddI) + LPV/r, Arm C: TDF/FTC + darunavir/ritonavir (DRV/r). Patients were eligible if above 18 years, failed a first line NNRTI based ART (confirmed HIV-1 RNA≥1 000 copies/mL), showed good adherence (≥80%) and signed informed consent. Efficacy was defined as a HIV-1 RNA <50 copies/mL at 48 weeks and was analysed in both intention to treat (ITT-FDA snapshot) and per protocol (PP). Sample size was calculated for a power of 80% to show non inferiority with a margin of 15% and two-sided 95% confidence intervals. Results: From January 2010 to October 2012, 454 patients were randomized. Participants were mainly women (72%), had been on ART for a median duration of 49 months (IQR 33- 69), had a median CD4 count of 183 cell/mm3 (IQR 87 - 290) and a median plasma HIV-1 RNA (VL) of 4.5 log10 (IQR 4 - 5.1). All but 6 had resistance to at least one first line drug and 95% to 2 classes. At week 48 (cf table), 294 (65.2%) of the 451 analysed participants had an HIV-1 RNA<50 copies/mL, while 275 (83.2%) and 410 (90.9%) had a VL below 200 and 1 000 copies/mL respectively. Primary results in ITT showed a difference of 5.6% (IC95% -5.1; 16.4) and 6.1% (IC95% -4.5; 16.7) between the reference arm A and arms B and C respectively, excluding non-inferiority. In multivariate analysis, VL ≤ 100 000 copies/ml at baseline was independent predictor of viral suppression. No difference among arms was observed in median CD4 gain (+127 cells/uL), mortality or severe adverse events. No Protease mutations were observed in patients failing second line. Conclusions: Despite multiple NRTI mutations, PI/b based second line regimens showed satisfactory results. However, results for patients with high viral load at switch to second line are of special concern. The WHO recommended regimen remains a valid option.